Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) with Kirsten RAt Sarcoma 2 viral oncogene homolog (KRAS) mutation has become a clinical challenge in cancer treatment as KRAS-mutant tumors are often resistant to conventional anti-tumor therapies. Activated CDC42-associated kinase 1 (ACK1), an activator of protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiangjing, Liu, Jie, Qiu, Huawei, Hao, Huiting, Zhu, Jinhong, Peng, Shiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982072/
https://www.ncbi.nlm.nih.gov/pubmed/32530390
http://dx.doi.org/10.17305/bjbms.2020.4746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982072/
https://www.ncbi.nlm.nih.gov/pubmed/32530390
http://dx.doi.org/10.17305/bjbms.2020.4746

Ejemplares similares